CompuVax, Inc. announces issuance of patent in Europe and China for key RSV antigens
Del Mar, August 17, 2015
CompuVax, Inc. announces the issuance of a patent covering key antigens for vaccines against the respiratory syncytial virus. These antigens are based on epitopes of the broadly neutralizing antibody motavizumab and the engineering of epitope scaffolds at Bill Schief's laboratory.
The Chinese patent was issued on March 11, 2015 and the European Patent was issued on August 12, 2015. The duration of both patents is until October 5, 2031.
The patents were issued to the University of Washington and are exclusively licensed worldwide to CompuVax, Inc.